Pfizer Inc. (PFE)

41.85
NYSE : Health Technology
Prev Close 42.35
Day Low/High 41.83 / 42.62
52 Wk Low/High 34.32 / 46.47
Avg Volume 26.13M
Exchange NYSE
Shares Outstanding 5.55B
Market Cap 235.12B
EPS 1.90
P/E Ratio 22.29
Div & Yield 1.44 (3.27%)
Best Tech Stocks to Buy -- No Matter What Apple Reports

Best Tech Stocks to Buy -- No Matter What Apple Reports

Tech is still the equity market's leading sector over three months -- and over most timeframes going back years.

Global Stocks Mixed Amid Extended Tech Woes; BoJ Moves Boost Bond Markets

Global Stocks Mixed Amid Extended Tech Woes; BoJ Moves Boost Bond Markets

Global stocks continued to edge lower Tuesday, as tech sector weakness bled into markets in Asia following last night's sell off on Wall Street, putting even more pressure on today's third quarter earnings report from Apple at the close of trading today.

PFIZER REPORTS SECOND-QUARTER 2018 RESULTS

PFIZER REPORTS SECOND-QUARTER 2018 RESULTS

Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2018 and raised 2018 financial guidance for Adjusted diluted EPS (2).

Apple, Federal Reserve, Pfizer, General Electric, CBS - 5 Things You Must Know

Apple, Federal Reserve, Pfizer, General Electric, CBS - 5 Things You Must Know

U.S. stock futures are rising slightly on Tuesday ahead of earnings from Apple and as a two-day meeting of the Federal Reserve gets set to begin.

Pfizer Receives European Approval For Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

Pfizer Receives European Approval For Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has approved TRAZIMERA™, 1 a biosimilar to Herceptin ®* (trastuzumab), for the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing...

Dow Ends Near Day's Lows as Tech Slump Hits Shares

Dow Ends Near Day's Lows as Tech Slump Hits Shares

Stocks ended lower on weakness in tech shares and after a strong report from Caterpillar proved insufficient to prop up the Dow.

Jim Cramer: How to Pick Stocks When the Market Is Flying Blind

Jim Cramer: How to Pick Stocks When the Market Is Flying Blind

This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.

Earnings On Pace For Most 'Beats' in a Decade as Tariffs Pose Few Concerns

Earnings On Pace For Most 'Beats' in a Decade as Tariffs Pose Few Concerns

U.S. companies are on pace for one of the best earnings seasons in a decade, according to mid-term data from FactSet, with most firms appearing to have little or no concern for the impact of trade and tariffs on their bottoms lines over the coming months.

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Shares fell on Friday morning despite positive results for the second quarter.

The Race to Cure Alzheimer's is On: These Are the Forerunners

The Race to Cure Alzheimer's is On: These Are the Forerunners

Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.

ViiV Healthcare Announces SWORD 100-week Data For Juluca (dolutegravir/rilpivirine) At AIDS 2018

ViiV Healthcare Announces SWORD 100-week Data For Juluca (dolutegravir/rilpivirine) At AIDS 2018

ViiV Healthcare today presented 100-week results from its phase III programme evaluating the safety and efficacy of switching virologically-suppressed people living with HIV (PLHIV) from a three or four-drug antiretroviral regimen to a 2-drug regimen of...

ViiV Healthcare Presents Phase III Data At AIDS 2018 From Landmark GEMINI Studies Showing Two-Drug Regimen Of Dolutegravir And Lamivudine Has Similar Efficacy To A Three-Drug Regimen In Treatment Naïve HIV Patients, With No Emergence Of Resistance

ViiV Healthcare Presents Phase III Data At AIDS 2018 From Landmark GEMINI Studies Showing Two-Drug Regimen Of Dolutegravir And Lamivudine Has Similar Efficacy To A Three-Drug Regimen In Treatment Naïve HIV Patients, With No Emergence Of Resistance

ViiV Healthcare today presented at the 22 nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 & 2 studies, assessing the safety and efficacy of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC)...

Broker Darlings Of The Dow: Pfizer Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Pfizer Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #10 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Pfizer Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #110 spot out of 500.

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

These blue chips pay shareholders handsomely in the form of dividends and share buybacks.

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 7/20/18)

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 7/20/18)

Why study charts? Because they're like footprints at the scene of the crime, clues to what the big money managers are likely thinking, Jim Cramer says.

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

The pharmaceutical giant's American depository receipts jumped on the heels of a report that the company's chairman is mulling a breakup of the firm.

U.S. FDA Approves Pfizer's Biosimilar NIVESTYM™ (filgrastim-aafi)

U.S. FDA Approves Pfizer's Biosimilar NIVESTYM™ (filgrastim-aafi)

Pfizer Inc. (NYSE:PFE) today announced that the United States (U.

Three Key Takeaways From Healthcare Earnings Season

Three Key Takeaways From Healthcare Earnings Season

Drug pricing remains front and center as healthcare companies start reporting quarterly results.

5 Big Biotech Stories to Watch

5 Big Biotech Stories to Watch

The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.

Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain

Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain

Pfizer Inc.(NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met...

Be Alert For Buying Opportunities: Cramer's 'Mad Money' Recap (Monday 7/16/18)

Be Alert For Buying Opportunities: Cramer's 'Mad Money' Recap (Monday 7/16/18)

Jim Cramer says this market is all about being opportunistic, about being willing to fight the tide.

Four Great, Conservative Income Stocks

From Coca-Cola to Pfizer, these blue chips offer well-supported dividend payouts.

Jim Cramer: Sometimes You Just Have to Go Against the Grain

Jim Cramer: Sometimes You Just Have to Go Against the Grain

This market is all about being opportunistic.

Pfizer Initiates Pivotal Phase 3 Program For Investigational Hemophilia B Gene Therapy

Pfizer Initiates Pivotal Phase 3 Program For Investigational Hemophilia B Gene Therapy

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study ( NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in...

U.S. FDA Approves XTANDI® (enzalutamide) For The Treatment Of Men With Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

U.S. FDA Approves XTANDI® (enzalutamide) For The Treatment Of Men With Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.

Pfizer Becomes #7 Most Shorted Dow Stock, Replacing Chevron

Pfizer Becomes #7 Most Shorted Dow Stock, Replacing Chevron

The most recent short interest data has been released for the 06/29/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Elliott Tackles AC Milan After Chinese Investors Falter; Pfizer Eyes Reorg-ICYMI

Elliott Tackles AC Milan After Chinese Investors Falter; Pfizer Eyes Reorg-ICYMI

Here's what you need to know now for Wednesday, July 11.

REPLAY: Jim Cramer on Tariffs, Oil Prices and Pfizer's Reorganization

REPLAY: Jim Cramer on Tariffs, Oil Prices and Pfizer's Reorganization

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.

TheStreet Quant Rating: B (Buy)